Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
Front Immunol ; 11: 603295, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33335531

RESUMEN

Eosinophilic esophagitis (EoE) is an antigen-driven disease associated with epithelial barrier dysfunction and chronic type 2 inflammation. Eosinophils are the defining feature of EoE histopathology but relatively little is known about their role in disease onset and progression. Classically defined as destructive, end-stage effector cells, eosinophils (a resident leukocyte in most of the GI tract) are increasingly understood to play roles in local immunity, tissue homeostasis, remodeling, and repair. Indeed, asymptomatic esophageal eosinophilia is observed in IgE-mediated food allergy. Interestingly, EoE is a potential complication of oral immunotherapy (OIT) for food allergy. However, we recently found that patients with peanut allergy may have asymptomatic esophageal eosinophilia at baseline and that peanut OIT induces transient esophageal eosinophilia in most subjects. This is seemingly at odds with multiple studies which have shown that EoE disease severity correlates with tissue eosinophilia. Herein, we review the potential role of eosinophils in EoE at different stages of disease pathogenesis. Based on current literature we suggest the following: (1) eosinophils are recruited to the esophagus as a homeostatic response to epithelial barrier disruption; (2) eosinophils mediate barrier-protective activities including local antibody production, mucus production and epithelial turnover; and (3) when type 2 inflammation persists, eosinophils promote fibrosis.


Asunto(s)
Alérgenos/efectos adversos , Antígenos/inmunología , Desensibilización Inmunológica/efectos adversos , Esofagitis Eosinofílica/inmunología , Eosinófilos/inmunología , Estenosis Esofágica/inmunología , Esófago/inmunología , Hipersensibilidad a los Alimentos/terapia , Administración Oral , Alérgenos/administración & dosificación , Animales , Progresión de la Enfermedad , Esofagitis Eosinofílica/metabolismo , Esofagitis Eosinofílica/patología , Esofagitis Eosinofílica/terapia , Eosinófilos/metabolismo , Estenosis Esofágica/metabolismo , Estenosis Esofágica/patología , Estenosis Esofágica/terapia , Esófago/metabolismo , Esófago/patología , Fibrosis , Hipersensibilidad a los Alimentos/inmunología , Hipersensibilidad a los Alimentos/metabolismo , Humanos , Factores de Riesgo , Transducción de Señal
2.
World J Gastroenterol ; 25(32): 4598-4613, 2019 Aug 28.
Artículo en Inglés | MEDLINE | ID: mdl-31528089

RESUMEN

Eosinophilic esophagitis is an immune-allergic pathology of multifactorial etiology (genetic and environmental) that affects both pediatric and adult patients. Its symptoms, which include heartburn, regurgitation, and esophageal stenosis (with dysphagia being more frequent in eosinophilic esophagitis in young adults and children), are similar to those of gastroesophageal reflux disease, causing delays in diagnosis and treatment. Although endoscopic findings such as furrows, esophageal mucosa trachealization, and whitish exudates may suggest its presence, this diagnosis should be confirmed histologically based on the presence of more than 15 eosinophils per high-power field and the exclusion of other causes of eosinophilia (parasitic infections, hypereosinophilic syndrome, inflammatory bowel disease, among others) for which treatment could be initiated. Currently, the 3 "D"s ("Drugs, Diet, and Dilation") are considered the fundamental components of treatment. The first 2 components, which involve the use of proton pump inhibitors, corticosteroids, immunosuppressants and empirical diets or guided food elimination based on allergy tests, are more useful in the initial phases, whereas endoscopic dilation is reserved for esophageal strictures. Herein, the most important aspects of eosinophilic esophagitis pathophysiology will be reviewed, in addition to evidence for the various treatments.


Asunto(s)
Esofagitis Eosinofílica/terapia , Eosinófilos/inmunología , Mucosa Esofágica/patología , Estenosis Esofágica/terapia , Diagnóstico Diferencial , Dietoterapia/métodos , Dilatación , Esofagitis Eosinofílica/diagnóstico , Esofagitis Eosinofílica/etiología , Mucosa Esofágica/citología , Mucosa Esofágica/diagnóstico por imagen , Estenosis Esofágica/inmunología , Esofagoscopía , Fibrosis , Reflujo Gastroesofágico/diagnóstico , Glucocorticoides/uso terapéutico , Humanos , Síndrome Hipereosinofílico/diagnóstico , Inmunosupresores/uso terapéutico , Enfermedades Inflamatorias del Intestino/diagnóstico , Enfermedades Parasitarias/diagnóstico , Inhibidores de la Bomba de Protones/uso terapéutico
4.
Gastroenterology ; 154(2): 333-345, 2018 01.
Artículo en Inglés | MEDLINE | ID: mdl-28757265

RESUMEN

Eosinophilic esophagitis is an emerging disease that is distinguished from gastroesophageal reflux disease by the expression of a unique esophageal transcriptome and the interplay of early life environmental factors with distinct genetic susceptibility elements at 5q22 (TSLP) and 2p23 (CAPN14). Rare genetic syndromes have uncovered the contribution of barrier disruption, mediated in part by defective desmosomes and dysregulated transforming growth factor beta production and signaling, to eosinophilic esophagitis pathophysiology. Experimental modeling has defined a cooperative role of activated eosinophils, mast cells, and the cytokines IL-5 and IL-13, mediated by allergic sensitization to multiple foods. Understanding these processes is opening the way to better treatment based on disrupting allergic inflammatory and type 2 cytokine-mediated responses, including anti-cytokine therapeutics and dietary therapy.


Asunto(s)
Citocinas/inmunología , Esofagitis Eosinofílica/etiología , Esofagitis Eosinofílica/terapia , Eosinófilos/inmunología , Esófago/patología , Hipersensibilidad a los Alimentos/inmunología , Adulto , Factores de Edad , Alérgenos/inmunología , Biopsia , Niño , Citocinas/genética , Citocinas/metabolismo , Síndrome de Ehlers-Danlos/epidemiología , Síndrome de Ehlers-Danlos/inmunología , Esofagitis Eosinofílica/epidemiología , Esofagitis Eosinofílica/patología , Epigénesis Genética , Estenosis Esofágica/etiología , Estenosis Esofágica/inmunología , Estenosis Esofágica/patología , Esófago/inmunología , Femenino , Fibrosis , Reflujo Gastroesofágico/etiología , Reflujo Gastroesofágico/patología , Microbioma Gastrointestinal/inmunología , Predisposición Genética a la Enfermedad/genética , Glucocorticoides/uso terapéutico , Humanos , Síndrome de Loeys-Dietz/epidemiología , Síndrome de Loeys-Dietz/inmunología , Masculino , Mastocitos/inmunología , Mastocitos/metabolismo , Prevalencia , Inhibidores de la Bomba de Protones/uso terapéutico , Factores Sexuales , Transcriptoma/genética
9.
Artículo en Alemán | MEDLINE | ID: mdl-2095648

RESUMEN

The postoperative complications were analysed in 64 patients after operation for stricture of the esophagus. The underfeeding in consequence of the esophagus stricture reduced the cellular immune functions and increased the operative risk. The comparison of the feeding and immune parameters of patients with benign and malign strictures of the esophagus showed that the poor immune reactivity is caused by the underfeeding first of all and not by the immune depression due the tumor.


Asunto(s)
Estenosis Esofágica/cirugía , Inmunidad Celular , Estado Nutricional , Complicaciones Posoperatorias/fisiopatología , Neoplasias Esofágicas/inmunología , Neoplasias Esofágicas/fisiopatología , Neoplasias Esofágicas/cirugía , Estenosis Esofágica/inmunología , Estenosis Esofágica/fisiopatología , Humanos , Activación de Linfocitos , Linfocitos/inmunología , Complicaciones Posoperatorias/inmunología , Factores de Riesgo , Formación de Roseta
13.
Vestn Khir Im I I Grek ; 130(3): 42-4, 1983 Mar.
Artículo en Ruso | MEDLINE | ID: mdl-6857955

RESUMEN

The authors have studied the significance of factors of the humoral non-specific defense (HND) in 37 patients with cicatricial constrictions of the oesophagus and stomach. The data obtained were used for choosing the optimum terms for gastrostoma and oesophagoplasty. In 14 patients treatment with lysozyme was performed due to decreased indices of HND.


Asunto(s)
Proteínas del Sistema Complemento/deficiencia , Estenosis Esofágica/inmunología , Muramidasa/deficiencia , Quemaduras Químicas/complicaciones , Humanos , Síndromes de Inmunodeficiencia/tratamiento farmacológico , Muramidasa/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA